Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Return for 7 May 2026, detailing a small-scale share repurchase on the Hong Kong Stock Exchange.

Key transaction details • Date: 7 May 2026 • Volume: 16,600 H-shares • Price range: HK$31.08–HK$31.70 per share • Aggregate consideration: HK$0.52 million, implying a volume-weighted average price of HK$31.35.

Capital structure impact • Outstanding shares (excluding treasury) decreased from 135,732,730 to 135,716,130. • Treasury holdings rose from 486,100 to 502,700 shares, lifting the treasury stake by 0.012 percentage points. • Total issued shares remained unchanged at 136,218,830.

Repurchase mandate utilisation • Shareholder mandate dated 12 February 2026 permits a maximum buyback of 13,621,883 shares. • Cumulative repurchases under this mandate now total 502,700 shares, equivalent to 0.37 % of the issued share base at the mandate date. • In accordance with Hong Kong Listing Rules, the company cannot issue new shares or dispose of treasury shares until 6 June 2026.

No shares from the latest repurchase have been cancelled; all are held as treasury stock. Chairman and Executive Director Zhang Faming confirmed that the transaction complied with the Hong Kong Stock Exchange’s Main Board Rules and domestic regulations.